A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of PF-04629991 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 06 May 2009
At a glance
- Drugs PF 4629991 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 06 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2009 Planned end date changed from 1 Mar 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.
- 16 Jan 2009 New trial record.